Micro-X Limited Overview
Micro-X is an Adelaide-based developer and vertically integrated manufacturer of X-ray imaging systems. Its systems are built on a proprietary cold-cathode carbon-nanotube (CNT) emitter platform branded "NEX" (Nano Electronic X-ray) Technology. The CNT emitters are switched electronically rather than heated, so the tubes and high-voltage generators are smaller, lighter and lower-power than conventional filament designs. This enables mobile radiography (the Rover/Rover Plus), a stationary multi-source Head CT for pre-hospital stroke diagnosis, a portable Full Body CT, and miniaturised CT baggage scanners for airport self-screening checkpoints. The business is pre-profit and has a material-uncertainty going-concern emphasis. Revenue is dominated by non-dilutive engineering contracts with US government agencies (DHS, ARPA-H), the Australian Stroke Alliance and industrial partners (Varex, Billion Prima), with a smaller and lumpy product business. In August 2026 a new technologist CEO launched a "strategic reset" focused on medical CT. It was funded by A$8M of secured 12% convertible notes.
Company's own description
The FY25 directors' report describes the principal activities as the design, development, manufacture and commercialisation of imaging products for global healthcare and security markets, using the company's proprietary cold-cathode X-ray technology [AR-FY25]. The standard "About Micro-X" boilerplate (2026) adds three points [ASX-03Aug26]:
-
The company has a fully vertically integrated design and production facility in Adelaide and a technical and commercial team in Seattle.
-
Its first mobile digital radiology products are sold for healthcare, military and veterinary imaging.
-
DHS has contracted it to design a next-generation airport checkpoint, a miniature brain CT for ambulances is government-funded, and ARPA-H contracted it in November 2024 to develop a full-body CT.
Independent characterisation
Micro-X is best understood as a platform-technology engineering house that is still converting into a product company. Its economic engine has three parts.
-
Funded development (largest revenue line). Government and corporate partners pay Micro-X to adapt NEX tubes and generators to their applications. Engineering contract services were A$10.463M of A$13.053M FY25 revenue (80%) [AR-FY25]. Revenue is recognised over time, on hours and inputs for fixed-price contracts and on time-and-materials for DHS.
-
Product sales (Mobile DR). The Rover / Rover Plus mobile X-ray carts, imaging chains and spare parts are sold direct and via distributors to hospitals, militaries, NGOs (Ukraine), elite sports teams and veterinary users. Product revenue is highly lumpy: A$6.410M in FY24, A$2.590M in FY25, and A$4.405M in H1 FY26 alone, of which A$3.36M was one Malaysian MoH order [AR-FY25, HY26].
-
Component and licensing economics (emerging). These include the A$7.5M exclusive multi-beam tube licence to Varex Imaging (FY23) and a model under which Billion Prima buys Micro-X tubes and generators for each baggage/parcel scanner it sells (from its planned 2026 launch) [AR-FY23, AR-FY25].
A fourth, non-operating support is the Australian R&D Tax Incentive (RDTI). It contributed A$6.647M (FY23), A$6.373M (FY24) and A$5.430M (FY25) of "other income" [AR-FY23, AR-FY25]. Only companies with aggregated turnover below A$20M qualify for the refundable cash offset. This creates a perverse threshold effect: management did not book RDTI in H1 FY26 because it was unsure it would stay under A$20M [HY26]. FY26 revenue ended at A$15.087M [4E-FY26], and about A$2M of net FY26 RDTI is expected in October 2026 [4C-Q4FY26].
Revenue model mix
| Revenue type (AUD Mn) | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sale of goods (product) | 3.795 | 6.410 | 2.590 |
| Engineering contract services | 11.210 | 8.812 | 10.463 |
| Total revenue | 15.005 | 15.222 | 13.053 |
| Other income (mostly RDTI) | 7.390 | 6.740 | 5.591 |
Sources: [AR-FY23], [AR-FY25]. Subscription or recurring service revenue is not separately disclosed and appears immaterial. Licensing appears inside engineering services (Varex).
Value-chain position
Micro-X is vertically integrated from the core component (CNT emitter, X-ray tube, solid-state epoxy-encapsulated high-voltage generator delivering 160 kV DC [AR-FY23]) through to system integration (Rover carts, CT arrays, checkpoint portals) and reconstruction software and algorithms. It buys detectors (e.g., Varex Lumen glass-free detector on Rover 2026 [HY26]), millimetre-wave body scanning (Voxel Radar) and AI threat-detection collaborations (Johns Hopkins) from third parties [AR-FY25].
Customer types and end-markets
| End-market | Customer types | Representative customers / counterparties |
|---|---|---|
| Hospital & ambulatory radiology | Health systems, GPOs, distributors | Unnamed major US provider (>700 facilities, Jul 2025 supply agreement); Malaysian MoH via IMS; Vertec Scientific (UK) |
| Military / humanitarian | Defence forces, NGOs, governments | Australian Defence Force (JP2060 Ph3); Ukraine (13 charity-funded + 16 Australian-government-funded Rovers) |
| Sports medicine | Professional teams | 9 Rover Plus systems across 8 MLB teams; NHL Arizona Coyotes; first NBA team (H1 FY26) |
| Pre-hospital stroke (development) | Ambulance services, hospitals | Australian Stroke Alliance / Royal Melbourne Hospital |
| Rural / mobile CT (development) | US health agencies | ARPA-H |
| Aviation security (development) | US government | DHS Science & Technology Directorate / TSA labs |
| Cargo / parcel security (partner) | OEM | Billion Prima (Malaysia) |
| OEM components / licensing | X-ray tube OEMs | Varex Imaging |
Strategy
Strategic themes over time
FY23 "Strategy Refresh" (Aug 2023): Leverage the technology for commercial benefit; target larger, less competitive markets; de-risk and cut costs; use partnerships to create value; create recurring revenue [AR-FY23].
Jan 2025 "Strategy reset.": Focus on medical imaging (Rover Plus, Head CT, Full Body CT); discontinue Argus; seek partners to monetise security assets (Checkpoints, baggage scanner); pursue funded development only [AR-FY25].
Aug 2026 "Strategic reset" (FY27) [ASX-03Aug26]: 1. Medical CT priority. Development refocused on medical CT, which the company calls its largest future market. Imaging trials run in Melbourne, with Adelaide to follow.
-
Financial rigour. New CFO; stronger project cost control, capital allocation and board reporting.
-
Restructured Rover sales. A 10-week review by Seattle consultancy Altus Alliance led to CRM, pipeline, tender strategy and scalable resourcing changes ahead of the Rover 2026 launch.
-
Cost savings. >A$3M annualised (about A$2M employment, A$1M overhead), about 15% of the FY26 core cost base; substantially implemented, with the balance in H1 FY27.
-
Funding runway. Stated to extend through FY27, supported by A$8.1M of contracted development receipts from FY27 onward (milestone-dependent).
Initiatives register (last 24 months)
| Initiative | Date | Type | Detail |
|---|---|---|---|
| ARPA-H Full Body CT | Nov/Dec 2024 → ongoing | New business / funded R&D | Up to A$25M; CDR complete Jun 2026 |
| Argus discontinuation | Jan 2025 | Portfolio pruning | ~A$0.7M p.a. savings; A$1.871M impairment |
| Billion Prima partnership | Feb 2025; expanded Dec 2025 | Partnership + equity | A$5.6M development deal; A$5.4M total equity |
| Security monetisation process | 2025–26 | Strategic review | Engagement with multiple parties; no deal announced |
| US health-system supply agreement | Jul 2025 | Commercial | Framework with >700-facility provider; no initial orders on signing |
| IGP ambulance Head CT grant | Sep 2025 | Grant | A$4.4M |
| Rover 2026 | Nov 2025 | Product refresh | Varex Lumen detector |
| Lung CT research | Jun 2026 | Platform extension | A$1.3M to Micro-X |
| Sustainability strategy | FY25 → reporting from 1 Jul 2026 | ESG | Voluntary AASB S1/S2-referenced disclosures |
| Convertible-note-funded reset | Aug 2026 | Capital / transformation | A$8M notes; use of proceeds: ~45% Head CT, ~20% Rover launch, ~20% opex, ~10% working capital, ~5% costs |
Medium-term targets / guidance
Micro-X does not publish revenue or earnings guidance. Stated objectives are:
-
Head CT regulatory submission by the end of 2026 [HY26].
-
Funding runway through FY27 [ASX-03Aug26].
-
Improving net operating cash flow in coming quarters, with about A$2M of net FY26 RDTI expected in October 2026 [4C-Q4FY26].
-
Achieving "cashflow stability" via CT products [ASX-03Aug26].
Products & Services
Core platform: NEX (Nano Electronic X-ray) Technology
Description: Patented cold-cathode emitter containing millions of carbon nanotubes that emit electrons by field emission into an anode. There is no heated filament, which allows instant electronic on/off switching and a controllable focal spot [AR-FY23].
Components: CNT X-ray tubes (including the "mini tube" for CT arrays) and an in-house solid-state high-voltage generator. The generator is epoxy-encapsulated, delivers 160,000 V DC and was commercialised in 2023 [AR-FY23].
Commercial history: First NEX tubes commercially produced in 2019 [AR-FY23].
Monetisation routes: Embedded in own products, licensed (Varex multi-beam), and supplied as components (Billion Prima).
Medical imaging: commercial
| Product | Description & key capabilities | Target customer | Launch / latest version | Pricing / channel | Status |
|---|---|---|---|---|---|
| Rover Plus | Ultra-mobile digital radiography cart on NEX tube and in-house generator; lightweight, manoeuvrable, ruggedised; FDA 510(k) (with Varex flat-panel detector) and ARTG listed | Hospitals, urgent care, military field hospitals, NGOs, sports teams, vets | Launched Sep 2022 [AR-FY23] | Direct and distributors (MXR, Medlink historically; Vertec UK; IMS Malaysia). Unit pricing not disclosed. Framework pricing with major US provider. | Commercial; restructured sales function from FY27 |
| Rover 2026 (updated Rover) | Glass-free Varex Lumen detector, integrated detector charging, larger screen, streamlined chassis | Same | Unveiled at RSNA Nov 2025; "available shortly" per [HY26]; commercial launch funded by convertible notes [ASX-03Aug26] | — | Launching FY27 |
| Rover (original) | Ruggedised successor to Nano; proven in Ukraine front-line surgical units | Military/humanitarian | c. 2019 | Direct | Legacy |
| Nano / DRX-Revolution Nano | First-generation mobile DR; OEM version sold via Carestream | Hospitals | c. 2017 | OEM | Wound down (nil FY25 revenue) |
| Imaging chains | NEX tube + generator + control sub-system sold as a module | OEMs, partners | First reported FY25 (A$0.481M) | — | Active |
| Spare parts & service | Replacement parts, servicing | Installed base | Ongoing | — | A$0.3M p.a. |
Medical imaging: development
| Product | Description | Funding | Stage (latest) | Next milestones |
|---|---|---|---|---|
| Head CT ("Stroke Scanner", formerly Brain CT) | Stationary cone-beam CT using an array of purpose-built NEX mini tubes (21 tubes per FY23 design) in a curved arc; designed to fit road and air ambulances to diagnose stroke type within the "golden hour" | A$8.0M ASA contract (MRFF-funded "Stroke Golden Hour"); A$4.4M Industry Growth Program grant for the ambulance configuration | First full 3D phantom images FY25. First test bench at Royal Melbourne Hospital in Feb 2026. Human imaging pilot from 3 Jun 2026; multi-centre pilot recruiting 100+ patients (~108) with blind comparison to conventional CT; first CNT cone-beam CT human brain images reported. | Second and third test benches (Adelaide to follow); regulatory submission targeted by end-2026 [HY26]; ambulance trial |
| Full Body CT | Portable, lightweight full-body CT for rural and remote US patients, leveraging Head CT mini tubes and algorithms | ARPA-H contract up to A$25M (US$16.4M). Initial two-year A$12.5M component. Some media (Stockhead) reported "up to US$25M"; company filings state A$25M / US$16.4M. | Design concept and preliminary design reviews done (A$2.7M, H1 FY26); Critical Design Review (Milestone 7) Jun 2026 (A$1.6M) | Build full-size engineering prototype / test bench; imaging studies toward FDA |
| Lung CT (research) | Feasibility of a stationary NEX CT array for early lung-cancer screening; laboratory test bench only, not a clinical device | A$1.9M Critical Technologies Challenge Program; Micro-X receives A$1.3M for hardware, support and services | Agreement executed Jun 2026; 18-month program led by University of Sydney | Lab feasibility results |
Security products
| Product | Description | Funding / partner | Status |
|---|---|---|---|
| Passenger Self-Screening Checkpoint | Replaces the conveyor-plus-walk-through lane with seven self-screening stations in the same footprint, scanning passenger and bag simultaneously. Integrates Micro-X CT baggage scanner, Voxel Radar mm-wave body scanning, Johns Hopkins deep-learning models and Monash Design Health Collab design. | DHS S&T; total program up to US$20.9M (A$31.7M) | One checkpoint portal and two baggage scanners in TSA lab evaluation; two more checkpoints manufactured; extension to 30 Sep 2026 for algorithm work |
| Miniaturised CT Baggage Scanner | Compact modular NEX-based CT for carry-on bags; potential standalone use (stadiums, prisons, buildings) | DHS S&T; Sep 2026 8-month extension (~A$1.05M) to improve imaging speed and design for manufacture | First prototype 2024; four prototype scanners built in total; upgraded design in progress |
| Billion Prima baggage & parcel scanner | Partner-branded X-ray scanner with NEX tubes and generators | A$5.6M partnership (A$3.2M development milestones plus equity) | Prototype delivered Sep 2025; shown at Kuala Lumpur expo Oct 2025; partner launch planned 2026; Micro-X earns per-unit component revenue |
| Argus X-ray Camera | Portable backscatter imager for explosive-ordnance disposal; stand-off imaging transmitted to a tablet over 1,500 m; iF Design Award | Previously Defence-supported | Discontinued 31 Jan 2025; A$1.871M impairment in FY25 |
| Mobile Backscatter Imager (historic) | Counter-IED predecessor concept, with Thales collaboration | — | Superseded by Argus, then discontinued |
Licensing
Varex multi-beam tubes: Exclusive global licence (A$7.5M / US$5.0M) for Varex to make multi-beam tubes using NEX. Technology transfer completed in FY25. Micro-X continues to customise its high-powered generator for Varex tubes [AR-FY23, AR-FY25].
Financial Narrative
Income statement
Sources: [AR-FY23] (FY22–23), [AR-FY25] (FY24–25), [4E-FY26]. FY22 revenue split: Mobile DR sales of A$3.8M stated in [AR-FY23]; engineering derived as the residual. FY22 growth is computed against FY21 revenue of A$3.77M (aggregator, TipRanks). Derived EBIT = pre-tax loss + finance expense. Derived EBITDA = EBIT + D&A. Both include RDTI other income. Gross profit is product-only because engineering services have no disclosed cost of sales.
Revenue CAGR FY22–FY26 (derived): 13.9%. FY23–FY26 CAGR: 0.2% (derived). Revenue has plateaued at A$13–15M for four years.
H1 FY26 bridge [HY26]: revenue A$10.107M (+155%); product A$4.405M; project A$5.702M; other income A$1.138M (vs A$3.440M; RDTI not booked); net loss A$6.617M (vs A$8.681M). Implied H2 FY26 revenue: A$4.98M (derived: 15.087 - 10.107). Implied H2 FY26 net loss: A$3.26M (derived; probably helped by catch-up RDTI recognition once the sub-A$20M turnover condition was confirmed).
Commentary.
FY23 inflection: Revenue rose 67% on the Varex technology transfer, DHS and ASA services. The loss narrowed 37%.
FY24: Flat revenue, but the mix shifted to product: A$3.0M of Ukraine and Australian military government sales lifted goods revenue to A$6.4M [AR-FY25].
FY25 regression: Rover sales collapsed 71% as the company pivoted to longer-cycle tenders. The Argus exit cost A$1.871M of impairment, and the loss widened to A$13.9M.
FY26 recovery: The Malaysian MoH order and ARPA-H milestones drove revenue +16% and loss -29%. The improvement relies on one A$3.36M order and milestone timing, not on a recurring run-rate.
Cost base: Employee costs have been stuck at A$16–17M p.a. since FY22 despite two cost programs (A$2M in 2023, A$0.7M Argus in 2025). The FY27 reset targets a further >A$3M (about 15% of the FY26 core operating cost base) [ASX-03Aug26]. This implies an FY26 core operating cost base of about A$20M (derived).
Balance sheet
Sources: [AR-FY23], [AR-FY25], [4E-FY26], [4C-Q4FY26] (FY26 cash, rounded). Note a discrepancy: [AR-FY25] reports FY25 net assets as A$7.548M on the balance sheet but A$7.458M in the going-concern note (apparent typographical transposition).
31 Dec 2025 (interim) [HY26]: total assets A$17.411M; cash A$4.896M; borrowings nil (R&D loan repaid Oct 2025); lease liabilities A$2.826M; total liabilities A$11.753M; equity A$5.658M; accumulated losses A$142.087M.
Commentary. Equity has fallen from A$34.2M (30 Jun 2021) to A$5.7M (Dec 2025). Cumulative losses exceed A$142M against A$142.8M of paid-in capital, which means essentially all capital raised since 2011 has been consumed. Debt has been limited to (i) leases on Tonsley and Seattle premises and (ii) short-term RDTI advance loans at 15–16%. The capital structure changes materially in FY27: A$8M of three-year secured convertible notes at 12% compounding monthly are secured over substantially all assets [ASX-03Aug26]. Inventory of A$4.0–4.3M is largely Rover-related and partly Argus (written down) and is a meaningful latent cash source.
Cash flow
Sources: [AR-FY23], [AR-FY25]. FY26 OCF is derived as H1 (-3.047 [HY26]) + Q3 (-2.7 [4C-Q3FY26]) + Q4 (-3.161 [4C-Q4FY26]). The H1 figure was depressed by A$3.985M because the ATO remitted the RDTI refund directly to the lender. On a normalised basis H1 FY26 OCF was +A$0.938M [HY26]. FY26 equity proceeds are the December 2025 placement headline (A$6.18M) [4E-FY26].
Commentary. Cumulative FCF burn over FY22–FY25 was about A$46.5M (derived). Equity raised over FY23–FY26 was about A$25.9M (derived). Partner and RDTI cash covered the gap. The burn has fallen from A$18M (FY22) to A$6–9M, but there is still no organic path to cash breakeven without (a) Rover volume or (b) large milestone receipts.
Ratios
All ratios are derived from [AR-FY23] and [AR-FY25]. ROIC, net debt/EBITDA and interest coverage are not meaningful because EBIT and EBITDA are negative. The cash conversion cycle is not meaningful because receivables are dominated by the RDTI receivable (A$5.39M of A$8.32M at FY25). H1 FY26 current ratio: 1.45 (derived).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment metric (AUD Mn) | FY25 | H1 FY26 |
|---|---|---|
Australia: external sales | 4.212 | 4.809 |
Australia: other revenue | 5.591 | 1.061 |
Australia: profit/(loss) before tax | -15.036 | -7.102 |
United States: external sales | 8.841 | 5.298 |
United States: other revenue | 0 | 0.077 |
United States: profit/(loss) before tax | 1.141 | 0.485 |
Group total revenue (incl. other) | 18.644 | 11.245 |
Group loss before tax | -13.895 | -6.617 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansProduct line revenue (AUD Mn)
| Product line revenue (AUD Mn) | FY24 | FY25 |
|---|---|---|
Micro-X Rover / Rover Plus | 5.346 | 1.561 |
DRX-Revolution Nano | 0.743 | 0 |
Spare parts | 0.321 | 0.302 |
Micro-X Argus | 0 | 0.246 |
Micro-X imaging chains | 0 | 0.481 |
Engineering contract services | 8.812 | 10.463 |
Total | 15.222 | 13.053 |
Counterparty revenue (AUD Mn)
| Counterparty revenue (AUD Mn) | FY24 | FY25 | H1 FY26 |
|---|---|---|---|
US DHS (checkpoint & baggage CT) | 4.2 | 4.570 | 1.956 |
ARPA-H (Full Body CT) | 0 | 3.192 | 3.031 |
Billion Prima (baggage/parcel scanner) | 0 | 1.899 | 0.464 |
Australian Stroke Alliance (Head CT) | 1.0 | 0.620 | 0.251 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 8.970 | 15.005 | 15.222 | 13.053 | 15.087 |
Revenue growth YoY (%) | 138.0 | 67.3 | 1.4 | -14.2 | 15.6 |
Sale of goods (AUD Mn) | 3.8 | 3.795 | 6.410 | 2.590 | — |
Engineering contract services (AUD Mn) | 5.2 | 11.210 | 8.812 | 10.463 | — |
Other income incl. RDTI (AUD Mn) | 4.144 | 7.390 | 6.740 | 5.591 | — |
Change in inventory / materials (AUD Mn) | -3.970 | -3.505 | -5.777 | -2.734 | — |
Product gross profit, derived (AUD Mn) | -0.170 | 0.290 | 0.633 | -0.144 | — |
Product gross margin, derived (%) | -4.5 | 7.6 | 9.9 | -5.6 | — |
Employee & director expenses (AUD Mn) | 15.894 | 17.019 | 16.623 | 17.252 | — |
Project development expenses (AUD Mn) | 4.444 | 6.444 | 3.708 | 4.338 | — |
Impairment (AUD Mn) | 0 | 0 | 0 | 1.871 | — |
Depreciation & amortisation (AUD Mn) | 1.432 | 1.589 | 1.539 | 1.570 | — |
Finance expenses (AUD Mn) | 0.296 | 0.269 | 0.248 | 0.561 | — |
Operating income (EBIT), derived (AUD Mn) | -16.793 | -10.485 | -9.517 | -13.334 | — |
EBITDA, derived (AUD Mn) | -15.361 | -8.896 | -7.978 | -11.764 | — |
Pre-tax income (AUD Mn) | -17.089 | -10.754 | -9.765 | -13.895 | -9.876 |
Net income (AUD Mn) | -17.089 | -10.754 | -9.765 | -13.895 | -9.876 |
EPS basic (A cents) | -3.71 | -2.17 | -1.85 | -2.28 | — |
EPS diluted (A cents) | -3.71 | -2.17 | -1.85 | -2.28 | — |
Dividends per share (A cents) | 0 | 0 | 0 | 0 | 0 |
EBITDA margin, derived (%) | -171.2 | -59.3 | -52.4 | -90.1 | — |
Operating margin, derived (%) | -187.2 | -69.9 | -62.5 | -102.2 | — |
Net margin (%) | -190.5 | -71.7 | -64.2 | -106.5 | -65.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 31.277 | 30.298 | 26.895 | 22.106 | — |
Cash & equivalents (AUD Mn) | 10.303 | 5.223 | 3.228 | 3.242 | 3.1 |
Trade & other receivables (AUD Mn) | 3.755 | 6.996 | 7.212 | 8.321 | — |
Inventories (AUD Mn) | 5.783 | 7.338 | 5.379 | 4.274 | — |
Total current assets (AUD Mn) | 22.744 | 22.437 | 19.898 | 17.080 | — |
Total current liabilities (AUD Mn) | 6.479 | 8.318 | 8.633 | 11.308 | — |
Working capital, derived (AUD Mn) | 16.265 | 14.119 | 11.265 | 5.772 | — |
Short-term borrowings (AUD Mn) | 0 | 0 | 0 | 3.375 | — |
Lease liabilities, current (AUD Mn) | 0.633 | 0.726 | 0.692 | 0.659 | — |
Lease liabilities, non-current (AUD Mn) | 4.681 | 3.977 | 3.298 | 2.499 | — |
Total debt incl. leases, derived (AUD Mn) | 5.314 | 4.703 | 3.990 | 6.533 | — |
Net debt / (net cash) incl. leases, derived (AUD Mn) | -4.989 | -0.520 | 0.762 | 3.291 | — |
Goodwill (AUD Mn) | 0 | 0 | 0 | 0 | — |
Intangibles (AUD Mn) | 0.144 | 0.132 | 0.120 | 0.024 | — |
Total liabilities (AUD Mn) | 11.988 | 13.105 | 12.634 | 14.558 | — |
Total equity (AUD Mn) | 19.289 | 17.193 | 14.261 | 7.548 | — |
Accumulated losses (AUD Mn) | -101.380 | -112.134 | -121.773 | -135.470 | — |
Issued capital (AUD Mn) | 117.529 | 125.396 | 131.933 | 138.350 | — |
NTA per share (A cents) | 4.15 | 3.33 | — | 1.14 | 0.68 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -18.108 | -10.993 | -6.435 | -8.591 | -8.9 |
Capex incl. intangibles (AUD Mn) | 1.112 | 0.779 | 0.369 | 0.100 | — |
Free cash flow, derived (AUD Mn) | -19.220 | -11.772 | -6.804 | -8.691 | — |
Proceeds from share issues (AUD Mn) | 0 | 7.455 | 5.921 | 6.365 | 6.18 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
RDTI cash refunds (AUD Mn) | 2.079 | 3.885 | 6.232 | 6.414 | — |
Receipts from customers (AUD Mn) | 4.099 | 3.894 | 6.990 | 2.788 | — |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on average equity (%) | -63.9 | -59.0 | -62.1 | -127.4 |
ROA on closing assets (%) | -54.6 | -35.5 | -36.3 | -62.9 |
Current ratio (x) | 3.51 | 2.70 | 2.30 | 1.51 |
Debt incl. leases / equity (x) | 0.28 | 0.27 | 0.28 | 0.87 |
Asset turnover, revenue / closing assets (x) | 0.29 | 0.50 | 0.57 | 0.59 |
Inventory days on product COGS, derived | 532 | 764 | 340 | 571 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY2024 | FY2025 |
|---|---|---|
United States | 9.463 | 9.040 |
Asia-Pacific | 4.324 | 2.979 |
Europe & EMEA | 1.435 | 1.034 |
Total | 15.222 | 13.053 |
Region growth / mix (%)
| Region growth / mix (%) | FY2024 | FY2025 |
|---|---|---|
United States share (%) | 62.2 | 69.3 |
Asia-Pacific share (%) | 28.4 | 22.8 |
Europe & EMEA share (%) | 9.4 | 7.9 |
United States YoY (%) | — | -4.5 |
Asia-Pacific YoY (%) | — | -31.1 |
Europe & EMEA YoY (%) | — | -27.9 |
Entity external sales (AUD Mn)
| Entity external sales (AUD Mn) | FY2025 | H1 FY2026 |
|---|---|---|
Micro-X Limited (Australia, incl. UK) | 4.212 | 4.809 |
Micro-X Inc (US) | 8.841 | 5.298 |
Share Price History
| Date | Price (AUD) | Context |
|---|---|---|
Sep 2023 (approx.) | 0.105 | After CEO appointment (AU Manufacturing, May 2023 reference: A$0.105, ~A$48.9M market cap) |
Apr 2024 | 0.095 | Placement and SPP price |
Mid-Sep 2024 | 0.050 | 12-month low (Stockhead) |
Early Dec 2024 | 0.097 | 12-month high (Stockhead) |
Feb 2025 | 0.070 | Placement / entitlement price |
30 Jul 2025 | 0.090 | US supply agreement spike |
Sep 2025 | 0.093 | IGP grant spike |
Dec 2025 | 0.080 | Placement price |
23 Feb 2026 | 0.070 | — |
30 Apr 2026 | 0.054 | Q3 4C release |
10 Jun 2026 | 0.038 | ARPA-H CDR |
24 Jul 2026 | 0.030 | — |
28 Aug 2026 | 0.026 | FY26 results |
Early Sep 2026 | 0.017 | Cycle low |
23 Sep 2026 | 0.041 | ASX price query |
8 Oct 2026 | 0.054 | Latest close |
Return (derived, approximate)
| Return (derived, approximate) | Value |
|---|---|
~1-year (Sep 2025 A$0.093 → Oct 2026 A$0.054) (%) | -42 |
~3-year (May 2023 A$0.105 → Oct 2026 A$0.054) (%) | -49 |
Valuation Multiples
| Multiple | Micro-X | Comment |
|---|---|---|
EV/Sales (FY26) | ~2.7x | EV ≈ market cap + leases (~A$2.8M) - cash (A$3.1M); excludes A$8M notes if settled |
P/B | ~7–8x | — |
Price / NTA | ~7.9x | NTA 0.68c per share (FY26) |
Capital Instruments
| Instrument | Amount (AUD Mn) | Rate | Maturity | Security |
|---|---|---|---|---|
Convertible notes (if fully settled) | 8.0 | 12% p.a., compounding monthly, cash or capitalised | ~Oct 2029 (3 years from issue) | General security deed over substantially all assets |
Lease liabilities (Dec 2025) | 2.826 | Implicit | Current 0.589; non-current 2.237 | Leased premises |
RDTI advance loans (historic) | 0 at Dec 2025 | 15–16% | Repaid from RDTI refunds | RDTI receivable |
Share Count (M) and Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Shares on issue at period end (M) | — | 514.4 | 581.6 | 667.2 | — |
Equity raised (AUD Mn) | 0 | 7.455 | 5.921 | 6.365 | 6.18 |
Analyst Conclusions
Management guidance and expectations
-
No numeric revenue or earnings guidance.
-
Stated objectives: Head CT regulatory submission by end-2026; funding runway through FY27; improving operating cash flow; about A$2M of FY26 RDTI in October 2026.
-
Contracted development receipts: A$8.1M from FY27 onward (milestone-dependent).
-
More than A$3M of annualised cost savings [HY26; 4C-Q4FY26; ASX-03Aug26].
-
Consensus (2 analysts): continued losses (FY27 EPS about -A$0.01); target A$0.15.
Bull case
-
Head CT is a category-creating asset. Human imaging is underway at RMH with 100+ patients targeted, and it is funded by MRFF (A$8M) plus IGP (A$4.4M). Success would make Micro-X the first company with an ambulance-deployable stationary CT for stroke, in a market the company sizes at US$5B.
-
Government partners keep paying. DHS (up to A$31.7M), ARPA-H (up to A$25M) and ASA fund the platform's development. Every disclosed ARPA-H milestone has been hit. CEO Gonzales personally originated these relationships.
-
Operating leverage is visible. H1 FY26 showed what a single tender (A$3.3M) does to revenue (+155%) and losses (-24%). Rover 2026, the 700-facility US framework, Billion Prima component sales and >A$3M of cuts could compound.
Bear case
-
Balance-sheet fragility. Cash was A$3.1M at June 2026 against an operating burn of about A$9M p.a. Going-concern emphasis has appeared in every recent set of accounts. Funding now relies on 12% secured debt that ranks ahead of equity.
-
Commercial execution has repeatedly disappointed. Argus failed. Rover revenue fell 71% in FY25. FY26 revenue (A$15.1M) missed consensus (A$26.9M) by 44%. The Chair has conceded execution shortfalls.
-
Dilution and structural drag. About 100M+ shares on note conversion, a large rights pool, and the RDTI cliff at A$20M revenue. Success itself could cut A$5–6M p.a. of tax-refund support just as scaling costs rise.
Catalysts and monitorables (next 12 months)
-
Settlement confirmation of the A$8M notes and director tranche (due by 2 Oct 2026).
-
Receipt of about A$2M of FY26 RDTI (Oct 2026); Q1 FY27 Appendix 4C (late Oct 2026).
-
AGM (Nov 2026 expected): remuneration vote, board renewal, any Billion Prima nominee.
-
Head CT pilot data readout and regulatory submission (target end-2026).
-
ARPA-H full-size prototype build milestones and payments.
-
Rover 2026 commercial availability; first orders under the US 700-facility framework.
-
Billion Prima scanner commercial launch and first component orders.
-
Any security-asset monetisation transaction.
-
DHS follow-on funding beyond the current extensions (federal FY27 budget).
-
H1 FY27 results (Feb 2027): first read on cost savings.
Analyst verdict
Micro-X is a genuinely differentiated technology company trapped in a small-cap funding loop. The technical record is credible. A cold-cathode CNT tube and generator stack has been industrialised in Adelaide. The world's largest tube OEM licensed it and invested in it. Two US federal agencies and an Australian clinical consortium have funded it into stationary-array CT systems that would be hard to build with conventional filament tubes. The Head CT human pilot that began in June 2026 is the most important de-risking event in the company's history. The Full Body CT program has passed every disclosed design gate.
The commercial record is weak. Over five years revenue has plateaued at about A$13–15M. Product gross margins have hovered near zero. One flagship product was abandoned. Losses have consumed essentially all A$142M of contributed capital. The August 2026 reset is a credible diagnosis: it narrows focus to CT, puts the originator of the government programs in charge, cuts costs and professionalises Rover selling. But its funding instrument, A$8M of 12% secured converts, tells investors that equity markets were effectively closed at prevailing prices. The capital structure is now senior-debt-heavy relative to the size of the business.
At about A$40M market cap and about 2.7x FY26 EV/sales, the equity is a long-dated, binary option on Head CT clinical and regulatory success and on Micro-X becoming a component supplier to larger partners. Non-dilutive government cash partly underwrites that option, but serial dilution and going-concern risk weigh on it. We characterise the stock as speculative / high-risk. Monitor the Head CT pilot data, Q1–Q2 FY27 cash burn against the >A$3M savings claim, and whether Rover 2026 converts the US framework into recurring orders. Absent at least two of these by mid-2027, a further recapitalisation on dilutive terms is the base case.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background / education | FY25 total remuneration (AUD) |
|---|---|---|---|---|
Dr Brian Gonzales | Chief Executive Officer (from 3 Aug 2026) | Joined 2017 (Lead Scientist); CSO & CEO of Micro-X Inc from 1 May 2023 | 21+ years in cold-cathode X-ray. PhD from University of North Carolina / NC State (CT algorithms with CNT X-ray). Secured the DHS program (US$3.5M grown to >US$16M awarded) and the US$16M ARPA-H program. Manages the Varex and Billion Prima partnerships (US$7M contract revenue 2023–26). | 529,046 (as CSO / CEO Americas) |
Peter Dickman | Chief Financial Officer | Since end-March 2026 | Prior roles not disclosed in sources reviewed | Not yet disclosed |
Anthony Skeats | — | COO since 1 May 2023 | MEng (Hons) | 535,063 |
Richard Willson | Company Secretary | Since 30 May 2025 | 25+ years as Company Secretary / NED / CFO across ASX tech and resources companies | n/a (KMP not disclosed) |
Kingsley Hall | Former CEO (1 May 2023 – 3 Aug 2026); adviser to 3 Nov 2026 | CFO from Feb 2020 | BEc (Flinders); 25+ years in finance and operations | 569,446 |
Board of Directors
| Director | Role | Appointed | Independence | Background | FY25 fees (AUD) | Shareholding |
|---|---|---|---|---|---|---|
Patrick O'Brien | Non-Executive Chair (Chair since 15 Jan 2025); chairs Audit & Risk and People & Remuneration per FY25 report | Aug 2015 | Independent NED (substantial shareholder) | Ex-Macquarie Senior MD (corporate finance, private equity), McKinsey, Minter Ellison; Chair GCQ Funds Management, CE Bartlett | 54,905 | 12,787,591 indirect shares + 526,316 options (Apr 2026); bought 2.5M at A$0.08 (Apr 2026) |
James McDowell | NED | Pre-FY22 | Independent | Ex-CEO BAE Systems Australia; ex-Deputy Secretary Naval Shipbuilding (Defence); ex-CE SA Dept Premier & Cabinet; NED Metal Powder Works (ASX:MPW) | 54,905 | 1,594,466 shares (FY25) |
Ilona Meyer | NED; Chair of Audit & Risk Committee | 7 Mar 2022 | Independent | General Counsel & CoSec, Nuix; ex-Boehringer Ingelheim, ResMed, Medtronic, 3M | 57,497 | 589,043 shares (FY25) |
Andrew Hartmann | NED (Varex nominee, unpaid) | 15 Dec 2022 | Not independent (major partner nominee) | SVP & GM Imaging Solutions, Varex; ex-Philips, Carestream, Siemens | 0 | 357,143 shares (FY25) |
Billion Prima nominee | NED (contractual right on tranche-2 settlement) | Expected by Mar 2026 | Not independent | — | — | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 May 2023 | Rowland → NED; Hall → CEO | Shift from founder-technologist to commercial leadership |
12 Nov 2024 | Gosling resigns | Board reduction |
15 Jan 2025 | Knox resigns; O'Brien Chair | Coincides with strategy reset |
30 May 2025 | Willson replaces Hall as CoSec | Governance separation |
Late Mar 2026 | Dickman appointed CFO | Strengthen financial controls |
3 Aug 2026 | Gonzales replaces Hall as CEO | The Chair said the company had not yet delivered commercial execution matching its technology; reset prioritises medical CT |
Major Shareholders
| Holder | Stake / position | Source |
|---|---|---|
Thorney Investment Group (Thorney Technologies Ltd et al.) | Substantial holder (≥5%); notice of dilution 2 Jan 2026. TIGA Trading (Thorney) is underwriter of A$2M of the convertible notes. | Form 604, 2 Jan 2026; [ASX-03Aug26] |
Billion Prima Sdn Bhd | About 8.6% after Dec 2025 placement (37.5M new shares at A$0.08 plus 26.7M at A$0.09 in 2025) | [HY26] |
Bindella Capital | Existing shareholder; committed A$5M of notes; would become substantial on conversion (62.5M shares at A$0.08) | [ASX-03Aug26] |
HSBC-custodied holder | Ceased to be substantial holder on 1 Sep 2026 after on-market sales | ASX Form 605, 3 Sep 2026 |
Patrick O'Brien (Chair) | About 12.8M shares | MarketIndex |
Directors & KMP aggregate | 15.56M shares at 30 Jun 2025 (about 2.3%) plus ~A$0.8M of notes committed (directors' portion subject to shareholder approval) | [AR-FY25]; [ASX-03Aug26] |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs. Micro-X |
|---|---|---|
Mobile DR | GE HealthCare (AMX Navigate / Optima mobile) | Incumbent; scale, service network, GPO contracts |
Mobile DR | Siemens Healthineers (Mobilett series) | Incumbent premium |
Mobile DR | Philips (MobileDiagnost) | Incumbent |
Mobile DR | Carestream Health (DRX-Revolution; former OEM partner) | Incumbent; ex-partner |
Mobile DR | Fujifilm (FDR Go / FDR nano) | Direct lightweight-cart competitor |
Mobile DR | Canon Medical, Shimadzu, Agfa (DR 100s), Konica Minolta | Broad competition |
Portable / point-of-care CT | Samsung NeuroLogica (OmniTom, CereTom) | Established portable head CT; rotating gantry |
Portable / point-of-care CT | Siemens Healthineers (SOMATOM On.site head CT) | Bedside head CT |
Point-of-care brain imaging (alternative modality) | Hyperfine (Swoop portable MRI) | Substitute for bedside neuro-imaging |
CNT / cold-cathode X-ray | Nanox (Nanox.ARC multi-source tomosynthesis) | Closest technology analogue |
CNT / cold-cathode X-ray | XinRay / Xintek (CNT tube pioneers) | Technology competitor |
Aviation CT screening | Smiths Detection, Rapiscan (OSI Systems), Leidos, Analogic | Incumbent checkpoint CT vendors with TSA certifications |
Peer Comparison FY2025
| Company | Latest FY revenue | Growth | Margin profile | R&D intensity |
|---|---|---|---|---|
Micro-X (FY26) | A$15.1M | +16% | Net margin -65% | ~95% of revenue (eligible R&D, derived from FY25) |
GE HealthCare (FY2024) | ~US$19.7B | ~flat | Profitable (low-to-mid-teens adjusted EBIT) | ~5–6% |
Siemens Healthineers (FY2024) | ~€22.4B | ~mid-single digit | Profitable | ~8–9% |
Nanox (FY2024) | ~US$11M | Growth from small base | Heavily loss-making | Very high |
Hyperfine (FY2024) | ~US$12.9M | Modest | Loss-making | High |
OSI Systems (FY2024, Jun YE) | ~US$1.54B | Double-digit | Profitable | ~4–5% |
Recent Developments
--



